The Fall 2016 Alzheimer's Association Topic Meeting, "Measuring Cognition in Early/Prodromal Stages of AD", will provide a forum for discussions of the targeted early/prodromal population and the tools and instruments currently available to identify these prevention trials to assess disease progression in the earliest stages of AD. Suitable cognitive, behavioral, functional, and biological endpoints for trials will be discussed. Finally, the current barriers to success for the development of therapeutics will be addressed. The meeting will allow experts in the field (academia, industry, regulators) to provide perspectives and experiences that may help establish a path forward for the development of new therapies in early/prodromal, clinically asymptomatic stages of Alzheimer's.